InvestSMART

Prana Biotechnology Limited (ASX: PBT) - Announcements

Current share price for PBT : $0.049 0.002 (4.26%)+

ASX company news and announcements for Prana Biotechnology Limited (PBT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Prana Biotechnology Limited (PBT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Prana Biotechnology Limited (PBT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Prana Biotechnology Limited (PBT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Commitments Test Entity - Fourth Quarter Report 31 Jul 2006 2:59PM $0.275 $0.049 fallen by 82.18%
- Additional Comment on PBT2 24 Jul 2006 1:38PM $0.490 $0.049 fallen by 90%
- PBT2 demonstrates rapid & potent effects 20 Jul 2006 9:53AM $0.215 $0.049 fallen by 77.21%
- PBT2-Phase IIa Clinical Trial-Alzheimer's Disease Patients 11 May 2006 4:15PM $0.200 $0.049 fallen by 75.50%
- Independent Report Received on PBT2 Phase 1 Clinical Trial 5 May 2006 9:20AM $0.210 $0.049 fallen by 76.67%
- Commitments Test Entity - Third Quarter Report 28 Apr 2006 10:54AM n/a $0.049 n/a
- Half Yearly Report & Half Year Accounts 7 Mar 2006 9:08AM $0.200 $0.049 fallen by 75.50%
- PBT2 successfully completes initial Phase 1 clinical trial 7 Feb 2006 9:25AM $0.210 $0.049 fallen by 76.67%
- Commitments Test Entity - Second Quarter Report 30 Jan 2006 4:52PM $0.195 $0.049 fallen by 74.87%
- Prof. Bush to present study findings at Neuroscience 2005 14 Nov 2005 4:11PM $0.265 $0.049 fallen by 81.51%
- PBT2 demonstrates safety in Phase 1 Human Trial 7 Nov 2005 9:32AM $0.220 $0.049 fallen by 77.73%
- Commitments Test Entity - First Quarter Report 28 Oct 2005 4:49PM $0.170 $0.049 fallen by 71.18%
- Appendix 4E - Preliminary Financial Report 9 Sep 2005 5:16PM $0.200 $0.049 fallen by 75.50%
- Commitments Test Entity - Fourth Quarter Report 29 Jul 2005 4:50PM $0.200 $0.049 fallen by 75.50%
- Management Change 16 Jun 2005 12:40PM $0.185 $0.049 fallen by 73.51%
- Completes Review of Development Program 16 Jun 2005 12:40PM $0.185 $0.049 fallen by 73.51%
- Trading Halt 16 Jun 2005 9:55AM $0.185 $0.049 fallen by 73.51%
- Cancels Plans for Placque Clinical Study 11 Apr 2005 1:34PM $0.300 $0.049 fallen by 83.67%
- Trading Halt 11 Apr 2005 9:38AM $0.300 $0.049 fallen by 83.67%
- Prana Receives Clinical Trials Authorisation in UK 4 Jan 2005 9:45AM $0.570 $0.049 fallen by 91.40%
- Raises US$3.7 Million Through Exercise of 9.5 MillionOptions 8 Dec 2004 10:48AM $0.540 $0.049 fallen by 90.93%
- Study reinforces positive Phase II results 12 Oct 2004 9:42AM $0.630 $0.049 fallen by 92.22%
- US Health Funds Invest USD 20 million in Prana Biotechnology 28 Apr 2004 9:13AM $0.920 $0.049 fallen by 94.67%
- Trading Halt 26 Apr 2004 9:54AM $1.000 $0.049 fallen by 95.10%
- Alzheimer's drug shows cont. promise in ext. clinical trial 16 Apr 2004 12:46PM $0.920 $0.049 fallen by 94.67%

301 - 325 of 331 results

Page 13 of 14

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.